OncoZenge submits application for PRIME status in the EU
Stockholm, Sweden, January 2[nd] 2024 – OncoZenge AB (publ), a leading biotechnology company developing BupiZenge™, an innovative, opioid-sparing treatment for oral pain, today confirms the submission of an application for PRIME (Priority Medicines) status with the European Medicines Agency (EMA).The PRIME initiative offers early, proactive, and enhanced support to accelerate the evaluation of promising medicines, to reach patients faster. To be eligible for PRIME, medicines must target an unmet medical need and show potential benefits for patients based on clinical data. BupiZenge™ is